23-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global Cancer gene therapy market in 2019 was approximately USD 800 million. The market is expected to grow at a CAGR of 23% and is anticipated to reach around USD 3,400 million by 2026.
Gene therapy is a method for curing or avoiding the substitution of mutated genes of health diseases. This replacement enables cells to produce valuable proteins. This may also affect the distribution of genes. This helps underactive or overactive genes to behave correctly. Gene therapy may be used for cells that alter their function or survival to express completely foreign genes. Genes are modified to destroy carcinogenic tumor cells all through cancer treatment. The demand for cancer gene therapy incorporates therapeutic DNA into the cancer treatment patient. It is known as an effective treatment for cancer because it causes limited side effects with optimum efficacy.
Browse the full “Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/cancer-gene-therapy-market-by-type-ex-vivo-898
Factors that contribute significantly to the growth of the world market for cancer gene therapy include an increasing number of cancer patients and an increasing geriatric population base. There is an increase in cancer patients worldwide every year. According to the WHO, cancer is the second leading cause of death in 2016. One death out of six deaths is also believed to have been caused by cancer. A further significant factor in the prevalence of gene therapy for cancer is the increase in R&D activities due to substantial investment in gene therapy for cancer. However, the high cost of treatment is a factor that has a negative effect on business development.
Based on the type, the cancer gene therapy market is segmented into ex-vivo and in-vivo therapy. Ex-vivo cancer gene therapy segment held the majority shares of around 55% in 2019, this surge for this segment is attributable to its increasing adoption of blood cancer treatment.
By Product, the market is bifurcated into viral vectors, non-viral vectors, and others. Non-viral vectors segment is projected to witness the growth of over 23% over the forecast period. The major driving factor for the growth of this segment is the low toxicity and immunogenicity of this vector, that reduces the risks of infections and allergies from patients suffering from cancer.
On the basis of region, North America dominated the cancer gene therapy market in 2019, owing to the presence of superior healthcare infrastructure. Moreover, the large presence of cancer patients and the aging population in the region is another factor fueling the growth of this region.
Some of the essential players operating in the Cancer gene therapy market, but not restricted to include Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics, and others.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 800 Million |
Projected Market Size in 2026 |
USD 3,400 Million |
CAGR Growth Rate |
23% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics, and BioBots. |
Key Segment |
By Product, By End-User, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
This report segments the Cancer gene therapy market as follows:
Global Cancer gene therapy Market: By Type Segmentation Analysis
Global Cancer gene therapy Market: By Product Segmentation Analysis
- Viral Vectors
- Non-viral Vectors
- Others
Global Cancer gene therapy Market: By End-User Segmentation Analysis
- Biopharma companies
- Research institutes
- Others
Global Cancer gene therapy Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
